Amundi Asset Management US’s Clovis Oncology, Inc. CLVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-258,176
Closed -$6.41M 1716
2019
Q1
$6.41M Sell
258,176
-6,924
-3% -$174K 0.01% 809
2018
Q4
$4.76K Sell
265,100
-107,200
-29% -$2.19M ﹤0.01% 842
2018
Q3
$10.9M Buy
372,300
+89,000
+31% +$3.45M 0.01% 715
2018
Q2
$12.9M Buy
283,300
+84,300
+42% +$4.1M 0.02% 654
2018
Q1
$10.5M Buy
199,000
+146,200
+277% +$8.53M 0.02% 668
2017
Q4
$3.59M Buy
+52,800
New +$3.69M 0.01% 936

Other funds holding CLVS

Amundi Asset Management US's CLVS Position: Q2 2019 in Review

Amundi Asset Management US sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 258,176 shares — an estimated $6.41M sold.

Amundi Asset Management US first reported a position in CLVS in Q4 2017 and held it in 6 quarters. The position peaked at $12.9M in Q2 2018. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Amundi Asset Management US reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 258,176 Clovis Oncology, Inc. shares in Q2 2019, an estimated $6.41M.
  • Amundi Asset Management US first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 6 quarters.
  • Amundi Asset Management US's Clovis Oncology, Inc. position peaked at $12.9M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Amundi Asset Management US's 13F filing for Q2 2019, filed 14 Aug 2019.